Fernando Del Valle-Nava, Díez-Cattini G F, Alfonso García-López, Francisco Ortega-Santana
Department of Glaucoma, Fundación Hospital Nuestra Señora de la Luz, IAP, Mexico City, Mexico.
J Curr Glaucoma Pract. 2019 Sep-Dec;13(3):116-118. doi: 10.5005/jp-journals-10078-1259.
To report a case and management of persistent hypotony with hypotony-induced maculopathy after CyPass device implant.
The CyPass was the first supraciliary device approved by FDA and commercially available. Efficacy studies showed adequate intraocular pressure (IOP)-lowering results in combination with phacoemulsification. Hypotony induced by suprachoroidal minimally invasive glaucoma surgery (MIGS) was reported to be lower than 3% in the population that comprised the COMPASS study.
A 57-year-old female patient with mild open-angle glaucoma with maximum topical medical therapy who underwent sequential bilateral CyPass implantation developed persistent hypotony. Device obstruction was induced through argon laser burns directed to the peripheral iris, and the device was no longer visible on follow-up examinations. Topical IOP-lowering medication was restarted (timolol-dorzolamide) and has since been controlled under 16 mm Hg, without progression on visual fields.
Argon laser burns directed to the peripheral iris to induce synechiae development that produces device obstruction are an effective technique to manage persistent hypotony after supraciliary CyPass implantation.
Here, authors show a novel approach for treatment of persistent hypotony secondary to CyPass implantation. In the knowledge of the authors, this is the first report that describes a noninvasive management for this complication, and this case could help other physicians to manage similar cases.
Fernando DV-N, Díez-Cattini GF, Alfonso G-L, Management of Persistent Hypotony after Supraciliary CyPass Implantation Using Argon Laser. J Curr Glaucoma Pract 2019;13(3):116-118.
报告1例CyPass装置植入术后持续性低眼压伴低眼压性黄斑病变的病例及处理情况。
CyPass是首个获美国食品药品监督管理局(FDA)批准并上市的睫状体上腔装置。疗效研究表明,其与超声乳化术联合应用可有效降低眼压。据COMPASS研究人群报告,脉络膜上腔微创青光眼手术(MIGS)引起的低眼压发生率低于3%。
一名57岁女性患者,患有轻度开角型青光眼,接受了最大程度的局部药物治疗,先后双侧植入CyPass后出现持续性低眼压。通过氩激光烧灼周边虹膜导致装置阻塞,随访检查时装置不再可见。重新开始局部降眼压药物治疗(噻吗洛尔-多佐胺),此后眼压控制在16 mmHg以下,视野无进展。
通过氩激光烧灼周边虹膜以诱导形成粘连从而造成装置阻塞,是处理睫状体上腔CyPass植入术后持续性低眼压的有效技术。
本文作者展示了一种治疗CyPass植入术后持续性低眼压的新方法。据作者所知,这是首篇描述该并发症非侵入性处理方法的报告,该病例有助于其他医生处理类似情况。
Fernando DV-N, Díez-Cattini GF, Alfonso G-L, 使用氩激光处理睫状体上腔CyPass植入术后的持续性低眼压。《当代青光眼实践杂志》2019年;13(3):116 - 118。